Anuh Pharma Ltd Stock Price Today (NSE: ANUHPHR)
Fundamental Score
Anuh Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Anuh Pharma Ltd share price today is ₹79.79, down 1.34% on NSE/BSE as of 17 June 2026. Anuh Pharma Ltd (ANUHPHR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹801.50 (Cr). The 52-week high for ANUHPHR share price is ₹114.83 and the 52-week low is ₹67.00. At a P/E ratio of 20.71x, ANUHPHR is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 13.41% and a debt-to-equity ratio of 0.00.
Anuh Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Anuh Pharma Ltd share price chart: -7.06% return over the past month. 52-week high ₹114.83, 52-week low ₹67.00.
Anuh Pharma Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹77.90 | ₹77.90 | ₹75.33 | ₹75.53 | 38.79K (Cr) | |
| ₹76.48 | ₹78.10 | ₹75.00 | ₹76.86 | 41.51K (Cr) | |
| ₹77.90 | ₹77.98 | ₹74.00 | ₹76.10 | 42.75K (Cr) | |
| ₹76.50 | ₹76.99 | ₹76.20 | ₹76.67 | 18.61K (Cr) | |
| ₹76.90 | ₹77.49 | ₹76.30 | ₹76.47 | 34.27K (Cr) | |
| ₹75.58 | ₹76.90 | ₹75.58 | ₹76.29 | 22.25K (Cr) | |
| ₹78.00 | ₹78.00 | ₹75.00 | ₹75.58 | 60.24K (Cr) | |
| ₹80.81 | ₹80.81 | ₹75.51 | ₹76.17 | 1.57L (Cr) | |
| ₹79.50 | ₹82.44 | ₹78.75 | ₹81.19 | 71.72K (Cr) | |
| ₹77.88 | ₹80.86 | ₹77.79 | ₹79.76 | 34.41K (Cr) |
Anuh Pharma Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹76.48 | ₹78.10 | ₹75.00 | ₹75.53 | -1.24% | |
| ₹81.20 | ₹86.81 | ₹74.00 | ₹76.10 | -6.28% | |
| ₹78.00 | ₹85.00 | ₹70.15 | ₹81.20 | +4.10% | |
| ₹75.10 | ₹80.00 | ₹67.00 | ₹67.00 | -10.79% | |
| ₹74.19 | ₹85.00 | ₹70.42 | ₹77.16 | +4.00% | |
| ₹82.25 | ₹82.25 | ₹69.27 | ₹72.64 | -11.68% | |
| ₹79.00 | ₹83.67 | ₹76.70 | ₹80.52 | +1.92% | |
| ₹90.80 | ₹90.80 | ₹76.25 | ₹77.02 | -15.18% | |
| ₹84.81 | ₹93.00 | ₹78.42 | ₹89.74 | +5.81% | |
| ₹88.89 | ₹93.00 | ₹82.01 | ₹83.47 | -6.10% | |
| ₹98.85 | ₹98.85 | ₹86.25 | ₹87.36 | -11.62% | |
| ₹109.82 | ₹114.83 | ₹93.50 | ₹97.03 | -11.65% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Cheap micro-cap API play, but watch those margins.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. Anuh Pharma closed its trading window on April 1st ahead of FY26 results. Technical momentum has shifted from bearish to mildly bearish.
CORE STORY (THE REAL GAME)
Anuh Pharma is an API manufacturer riding the wave of Indian pharma's backward integration. The play is on reducing import dependency and diversifying export markets beyond the US.
- Trading window closed ahead of FY26 results
- Technical momentum shifted to mildly bearish
- Recent profit decline raises margin concerns
- Strong FY26 results
- New order wins
- Margin recovery
- Micro-cap liquidity risk
- Profit decline in Q2 FY26
- Dependence on a few APIs
Promoter holding increased by 1.9%
Indian pharma industry projected to reach $130 billion by 2030
Yes - Free Cash Flow 5Y: ₹79.91 Cr
Margin recovery is key. If they can stabilize or improve margins in the next 2 quarters, the stock could re-rate. Otherwise, expect further downside.
Primary Thesis Risk
Margin compression will kill the thesis.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Anuh Pharma Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Anuh Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ANUHPHR across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Excellent ROCE Performance (17.24%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 20.71 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Consistent Growth Track Record (16.60% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (25.58% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (25.58% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (86.70x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹79.91 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (71.82%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Profit Decline Concern (-49.40%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Anuh Pharma Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Anuh Pharma Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Anuh Pharma LtdAnuh Pharma Ltd...Selected✓ ANUHPHR • 506260 | 63.9/100 | ₹79.79₹80 | ₹801.50₹801.50 | 20.71Average 20.7 Average | 13.41%Average 13.41% Average | 17.24%Good 17.24% Good | 0.00Excellent 0.0 Excellent | 25.58%Excellent 25.58% Excellent | 16.60%Excellent 16.60% Excellent | 1.88% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1796.50₹1797 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6553.50₹6554 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4350.40₹4350 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1390.30₹1390 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1290.40₹1290 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2262.90₹2263 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹1091.20₹1091 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2320.20₹2320 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1433.70₹1434 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5314.50₹5315 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Anuh Pharma Ltd PE Ratio History
Historical price-to-earnings ratio for ANUHPHR — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹4.72 | ₹80.52 | 17x |
| FY 2024 | ₹5.99 | ₹113.00 | 18.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Anuh Pharma Ltd Dividend History
Annual cash dividends paid by ANUHPHR — dividend yield 1.88%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹12.52 Cr |
| FY 2024 | ₹10.03 Cr |
| FY 2023 | ₹8.75 Cr |
| FY 2022 | ₹7.56 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Anuh Pharma Ltd Quarterly Performance
Latest quarterly metrics for ANUHPHR — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
12.01%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-49.40%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
16.60%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
25.58%
Compounded annual net profit growth over 5 years
Anuh Pharma Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ANUHPHR — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Anuh Pharma Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Anuh Pharma Ltd (ANUHPHR) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Anuh Pharma Ltd
About ANUHPHR (Anuh Pharma Ltd)
Anuh Pharma Ltd is a dynamic pharmaceutical manufacturer deeply rooted in the Indian landscape. With a strong focus on bulk drug and chemical production, the company serves as a cr...itical link in the pharmaceutical supply chain. Anuh Pharma boasts a diverse portfolio of active pharmaceutical ingredients (APIs), meticulously crafted to meet the rigorous demands of the global healthcare industry. Their offerings encompass a spectrum of therapeutic categories, reflecting their commitment to addressing a wide range of medical needs. From essential treatments for infectious diseases to innovative solutions for chronic conditions, Anuh Pharma strives to provide high-quality ingredients that contribute to the development of life-enhancing medications. Their strength lies in their understanding of complex chemical processes and their adherence to strict regulatory standards. Beyond its core API offerings, Anuh Pharma demonstrates a commitment to continuous innovation. The company is actively involved in the development of specialized products, including niche chemicals and intermediates, further solidifying its position as a versatile partner within the pharmaceutical sector. This proactive approach to product development allows Anuh Pharma to adapt to the evolving needs of the market and cater to the specific requirements of its clientele. Their expertise extends to several therapeutic areas, reflecting a comprehensive approach to healthcare solutions. This adaptability and dedication to innovation allows Anuh Pharma to make significant strides and add value to its partners. Anuh Pharma's business model revolves around providing reliable and cost-effective solutions to pharmaceutical companies worldwide. Their commitment to quality, consistency, and timely delivery has earned them a reputation as a trusted supplier. By maintaining stringent quality control measures throughout the manufacturing process, Anuh Pharma ensures that its products meet the highest industry standards. This dedication to excellence has fostered long-term relationships with key players in the pharmaceutical industry. Anuh Pharma continues to invest in research and development, as well as, technology, in order to build on their business model and ensure customer satisfaction.
Company Details
Key Leadership
Corporate Events
ANUHPHR Share Price: Frequently Asked Questions
What is the current share price of Anuh Pharma Ltd?
Anuh Pharma Ltd (ANUHPHR) trades at ₹79.79 on NSE and BSE. Market cap ₹801.50 (Cr). Educational data only.
What is the P/E ratio of Anuh Pharma Ltd?
Anuh Pharma Ltd has a P/E of 20.71x vs industry average 31.77x.
What is the Bull Run score for Anuh Pharma Ltd?
Anuh Pharma Ltd has a Bull Run score of 63.9/100 based on 25+ financial parameters.
Does Anuh Pharma Ltd pay dividends?
Anuh Pharma Ltd has a dividend yield of 1.88%. Past dividends don't guarantee future payments.
What is the ROE of Anuh Pharma Ltd?
Anuh Pharma Ltd has ROE of 13.41%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Anuh Pharma Ltd?
Anuh Pharma Ltd has debt-to-equity of 0.00.
Is Anuh Pharma Ltd a good investment?
Bull Run gives Anuh Pharma Ltd a score of 63.9/100. This is not investment advice — consult a SEBI-registered advisor.